HSPG2 and breast neoplasm: We have demonstrated that PLC-β2 expression strongly correlates with a poor prognosis of patients with breast tumors [18] and that, in breast tumor-derived cells with a triple negative phenotype, this PLC isozyme promotes migration and is necessary to sustain invasion capability [16].